IN

Indoco Remedies LtdNSE INDOCO Stock Report

Last reporting period 30 Sep, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

0.162

Micro

Exchange

XNSE - National Stock Exchange Of India

INDOCO.NS Stock Analysis

IN

Uncovered

Indoco Remedies Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.162

Dividend yield

0.41 %

Shares outstanding

92.182 B

Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 6,101 full-time employees. The company went IPO on 2005-01-07. The firm is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The firm caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.

View Section: Eyestock Rating